Quick Answer
Greenwich LifeSciences, Inc. reported Diluted EPS of $1.21 per share (loss) for fiscal year 2024.
Greenwich LifeSciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.21 | -75.4% |
| 2023 | -$0.69 | -13.1% |
| 2022 | -$0.61 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | -50.0% | +0.0% |
| June 30, 2025 | -$0.30 | -50.0% | -20.0% |
| March 31, 2025 | -$0.25 | -31.6% | -25.0% |
| September 30, 2024 | -$0.20 | -5.3% | +0.0% |
| June 30, 2024 | -$0.20 | -53.8% | -5.3% |
| March 31, 2024 | -$0.19 | -11.8% | +0.0% |
| September 30, 2023 | -$0.19 | -5.6% | -46.2% |
| June 30, 2023 | -$0.13 | -116.7% | +23.5% |
- Greenwich LifeSciences, Inc. showed a decrease of -75.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, Greenwich LifeSciences, Inc.’s diluted eps has declined by 98.4% (from $0.61 per share (loss) to $1.21 per share (loss)).
- The most recent figure is from Greenwich LifeSciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: